Ror2 signaling and its relevance in breast cancer progression

Frontiers in Oncology

Volumn 7, Issue JUN, 2017, Pages

  Bayerlová, Michaela ^a   Menck, Kerstin ^a   Klemm, Florian ^a   Wolff, Alexander ^a   Pukrop, Tobias ^a,b   Binder, Claudia ^a   Beißbarth, Tim ^a   Bleckmann, Annalen ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Breast cancer; Metastasis; Module; Network integration; Ror2; Wnt signaling

Indexed keywords

RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL INVASION; CELL METABOLISM; CONTROLLED STUDY; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ROR2 GENE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

EID: 85024097372     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00135     Document Type: Article

References (64)

1. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 27:1160-7. doi:10.1200/JCO.2008.18.1370
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature (2000) 406:747-52. doi:10.1038/35021093
3. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 100:8418-23. doi:10.1073/pnas.0932692100
4. Howe LR, Brown AMC. Wnt signaling and breast cancer. Cancer Biol Ther (2004) 3:36-41. doi:10.4161/cbt.3.1.561
5. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 68:3108-14. doi:10.1158/0008-5472.CAN-07-5644
6. Moon RT, Kohn AD, Ferrari GVD, Kaykas A. WNT and ß-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 5:691-701. doi:10.1038/nrg1427
7. De A. Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin (2011) 43:745-56. doi:10.1093/abbs/gmr079
8. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 13:11-26. doi:10.1038/nrc3419
9. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (2012) 204:17-33. doi:10.1111/j.1748-1716.2011.02294.x
10. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol (2012) 13:767-79. doi:10.1038/nrm3470
11. Klemm F, Bleckmann A, Siam L, Chuang HN, Rietkötter E, Behme D, et al. ß-catenin-independent WNT signaling in basal-like breast cancer and brain metastasis. Carcinogenesis (2011) 32:434-42. doi:10.1093/carcin/bgq269
12. Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, et al. Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both ß-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol (2014) 141:243-54. doi:10.1007/s00432-014-1824-y
13. Zhang S, Chen L, Cui B, Chuang H-Y, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One (2012) 7:e31127. doi:10.1371/journal.pone.0031127
14. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res (2013) 41:D991-5. doi:10.1093/nar/gks1193
15. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 4:249-64. doi:10.1093/biostatistics/4.2.249
16. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 104:311-25. doi:10.1093/jnci/djr545
17. Haibe-Kains B, Schroeder M, Bontempi G, Sotiriou C, Quackenbush J. genefu: relevant functions for gene expression analysis, especially in breast cancer. RBioconductor Version Dev (2011) 212
18. Bayerlová M, Klemm F, Kramer F, Pukrop T, Beißbarth T, Bleckmann A. Newly constructed network models of different WNT signaling cascades applied to breast cancer expression data. PLoS One (2015) 10:e0144014. doi:10.1371/journal.pone.0144014
19. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res (2004) 32:D277-80. doi:10.1093/nar/gkh063
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 102:15545-50. doi:10.1073/pnas.0506580102
21. Bleckmann A, Conradi L-C, Menck K, Schmick NA, Schubert A, Rietkötter E, et al. ß-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis (2016) 33:309-23. doi:10.1007/s10585-016-9780-3
22. Hagemann T, Robinson SC, Schulz M, Trümper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-a dependent up-regulation of matrix metalloproteases. Carcinogenesis (2004) 25:1543-9. doi:10.1093/carcin/bgh146
23. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2013) 29:15-21. doi:10.1093/bioinformatics/bts635
24. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 12:323. doi:10.1186/1471-2105-12-323
25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2010) 26:139-40. doi:10.1093/bioinformatics/btp616
26. Robinson MD, Smyth GK. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics (2008) 9:321-32. doi:10.1093/biostatistics/kxm030
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol (1995) 57:289-300
28. Bayerlová M, Jung K, Kramer F, Klemm F, Bleckmann A, Beißbarth T. Comparative study on gene set and pathway topology-based enrichment methods. BMC Bioinformatics (2015) 16:334. doi:10.1186/s12859-015-0751-5
29. Beissbarth T. [18] Interpreting experimental results using gene ontologies. In: Kimmel A, Oliver B, editors. Methods in Enzymology DNA Microarrays, Part B: Databases and Statistics. Academic Press (2006). p. 340-52. Available from: http://www.sciencedirect.com/science/article/pii/S0076687906110186
30. Bayerlová M. Pathway and Network Analyses in Context of Wnt Signaling in Breast Cancer. (2016). Available from: https://ediss.uni-goettingen.de/handle/11858/00-1735-0000-0028-86E1-F
31. Sadeghi A, Fröhlich H. Steiner tree methods for optimal sub-network identification: an empirical study. BMC Bioinformatics (2013) 14:144. doi:10.1186/1471-2105-14-144
32. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the dynamic tree cut package for R. Bioinformatics (2008) 24:719-20. doi:10.1093/bioinformatics/btm563
33. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika (1982) 69:553-66. doi:10.1093/biomet/69.3.553
34. Leung E, Kim JE, Askarian-Amiri M, Finlay GJ, Baguley BC. Evidence for the existence of triple-negative variants in the MCF-7 breast cancer cell population. Biomed Res Int (2014) 2014:e836769. doi:10.1155/2014/836769
35. McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer (2009) 101:209-14. doi:10.1038/sj.bjc.6605174
36. MacMillan CD, Leong HS, Dales DW, Robertson AE, Lewis JD, Chambers AF, et al. Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway. Sci Rep (2014) 4:6315. doi:10.1038/srep06315
37. Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells (2003) 8:645-54. doi:10.1046/j.1365-2443.2003.00662.x
38. Walsh MD, Clendenning M, Williamson E, Pearson S-A, Walters RJ, Nagler B, et al. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol (2013) 26:1642-56. doi:10.1038/modpathol.2013.101
39. Hoshi H, Sawada T, Uchida M, Saito H, Iijima H, Toda-Agetsuma M, et al. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol (2011) 38:619-27. doi:10.3892/ijo.2011.911
40. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A (2008) 105:3047-52. doi:10.1073/pnas.0712148105
41. Bai Y, Tan X, Zhang H, Liu C, Zhao B, Li Y, et al. Ror2 receptor mediates Wnt11 ligand signaling and affects convergence and extension movements in zebrafish. J Biol Chem (2014) 289:20664-76. doi:10.1074/jbc.M114.586099
42. Dwyer MA, Joseph JD, Wade HE, Eaton ML, Kunder RS, Kazmin D, et al. WNT11 expression is induced by estrogen-related receptor a and ß-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res (2010) 70:9298-308. doi:10.1158/0008-5472.CAN-10-0226
43. Nishioka M, Ueno K, Hazama S, Okada T, Sakai K, Suehiro Y, et al. Possible involvement of Wnt11 in colorectal cancer progression. Mol Carcinog (2013) 52:207-17. doi:10.1002/mc.21845
44. Ouko L, Ziegler TR, Gu LH, Eisenberg LM, Yang VW. Wnt11 signaling promotes proliferation, transformation, and migration of IEC6 intestinal epithelial cells. J Biol Chem (2004) 279:26707-15. doi:10.1074/jbc.M402877200
45. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer (2010) 9:55. doi:10.1186/1476-4598-9-55
46. Nomachi A, Nishita M, Inaba D, Enomoto M, Hamasaki M, Minami Y. Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A. J Biol Chem (2008) 283:27973-81. doi:10.1074/jbc.M802325200
47. Aman A, Piotrowski T. Wnt/ß-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. Dev Cell (2008) 15:749-61. doi:10.1016/j.devcel.2008.10.002
48. Ghosh MC, Collins GD, Vandanmagsar B, Patel K, Brill M, Carter A, et al. Activation of Wnt5A signaling is required for CXC chemokine ligand 12-mediated T-cell migration. Blood (2009) 114:1366-73. doi:10.1182/blood-2008-08-175869
49. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science (2002) 296:1046-9. doi:10.1126/science.1067431
50. Sherwood V. WNT signaling: an emerging mediator of cancer cell metabolism? Mol Cell Biol (2015) 35:2-10. doi:10.1128/MCB.00992-14
51. Sherwood V, Chaurasiya SK, Ekström EJ, Guilmain W, Liu Q, Koeck T, et al. WNT5A-mediated ß-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis (2014) 35:784-94. doi:10.1093/carcin/bgt390
52. Kohn AD, Moon RT. Wnt and calcium signaling: ß-catenin-independent pathways. Cell Calcium (2005) 38:439-46. doi:10.1016/j.ceca.2005.06.022
53. Chuang H-Y, Lee E, Liu Y-T, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol (2007) 3:140. doi:10.1038/msb4100180
54. Uray IP, Liang Y, Hyder SM. Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Lett (2004) 207:101-7. doi:10.1016/j.canlet.2003.10.021
55. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, et al. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res (2007) 5:881-90. doi:10.1158/1541-7786.MCR-07-0055
56. Zhu Y, Tian Y, Du J, Hu Z, Yang L, Liu J, et al. Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One (2012) 7:e37823. doi:10.1371/journal.pone.0037823
57. Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang H, et al. PGC1a promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res (2011) 71:6888-98. doi:10.1158/0008-5472.CAN-11-1011
58. Patil P, Bachant-Winner P-O, Haibe-Kains B, Leek JT. Test set bias affects reproducibility of gene signatures. Bioinformatics (2015) 31:2318-23. doi:10.1093/bioinformatics/btv157
59. Millar EKA, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol (2009) 27:4701-8. doi:10.1200/JCO.2008.21.7075
60. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 13:4429-34. doi:10.1158/1078-0432.CCR-06-3045
61. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 121:2750-67. doi:10.1172/JCI45014
62. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 10:515-27. doi:10.1016/j.ccr.2006.10.008
63. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 28:3271-7. doi:10.1200/JCO.2009.25.9820
64. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol (2011) 7:e1002240. doi:10.1371/journal.pcbi.1002240